about Geoff is the Chief Commercial Officer for Ensysce Biosciences. Ensysce is a clinical stage company which employs transformative chemistry to improve prescription drug safety using two technology platforms. Their lead compound is designed to deliver strong analgesia while reducing the risk of abuse and overdose.<br><br>Geoff’s experiences range from leading development teams in phase 1 to propelling products through launch and life cycle management. He studied at INSEAD and Henley Business Schools and started his career in Biochemistry in Newcastle, England. He began working in the Pharmaceutical Industry for Eli Lilly and then moved to Lundbeck where he ran the UK sales and Marketing division. Following Lundbeck, Geoff moved to ICI Pharmaceuticals as a global marketing manager and spent 15 years with ICI and AstraZeneca. He ran several business units including global pricing and strategic communications; he also led the AZ merger process in all markets outside the USA. Geoff moved from the UK to the US in 1999 to lead the Neuroscience division and, when he left AZ, he was Global SVP for CNS and Oncology drugs, an $8 Billion dollar business.<br><br>Geoff transitioned into Biotech and consulting where he assisted many major companies on launch strategy, leadership development, and positioning.<br><br>Geoff has held leadership roles in the UK, the US, Germany, and Global businesses. He led the development and launch of several market leading brands in the CNS/ pain and addiction areas including Nicorette, Seroquel and Zomig.
Log in to save this to your schedule, view media, leave feedback and see who's attending!
